Semantic Scholar uses AI to extract papers important to this topic.
Ipilimumab 3 mg/kg was the first agent to demonstrate improved survival in previously treated patients with metastatic melanoma… Expand Metastatic melanoma is the most aggressive form of skin cancer with a median overall survival of less than one year. Advancements… Expand BACKGROUND
Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved… Expand BACKGROUND
An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3… Expand As technological advances allow for the identification of tumor-associated antigens (TAAs) against which adaptive immune… Expand The primary goal of this Phase I study was to assess the safety and bioactivity of tumor lysate-pulsed dendritic cell (DC… Expand Diagnostic records from 338 canine oral melanomas in 338 dogs received at the Veterinary Medical Diagnostic Laboratory (1992-1999… Expand In recent years, it has become evident that T cells can recognize peptides of melanocytic lineage antigens such as gp100, MART-1… Expand The selectivity of monoclonal antibody J-5 (anti-gp 100, common ALL antigen) for normal and leukemic hemopoietic cells has been… Expand A monoclonal antibody designated PI153/3, which reacts with neuroblastoma and fetal brain, is shown to identify also a cell… Expand